0001193125-13-084129.txt : 20130228 0001193125-13-084129.hdr.sgml : 20130228 20130228160648 ACCESSION NUMBER: 0001193125-13-084129 CONFORMED SUBMISSION TYPE: SC 13D/A PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20130228 DATE AS OF CHANGE: 20130228 GROUP MEMBERS: ADVENT HEALTHCARE & LIFE SCIENCES III A LTD PARTNERSHI GROUP MEMBERS: ADVENT HEALTHCARE & LIFE SCIENCES III LIMITED PARTNERSHIP GROUP MEMBERS: ADVENT INTERNATIONAL LLC GROUP MEMBERS: ADVENT PARTNERS HLS III LIMITED PARTNERSHIP GROUP MEMBERS: AHLS III GP LIMITED PARTNERSHIP SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: Aegerion Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001338042 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 202960116 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13D/A SEC ACT: 1934 Act SEC FILE NUMBER: 005-85739 FILM NUMBER: 13652032 BUSINESS ADDRESS: STREET 1: 101 MAIN STREET STREET 2: SUITE 1850 CITY: CAMBRIDGE STATE: MA ZIP: 02142 BUSINESS PHONE: (617) 500-7867 MAIL ADDRESS: STREET 1: 101 MAIN STREET STREET 2: SUITE 1850 CITY: CAMBRIDGE STATE: MA ZIP: 02142 FORMER COMPANY: FORMER CONFORMED NAME: Aegerion Pharmaceuticals Inc DATE OF NAME CHANGE: 20050906 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: ADVENT INTERNATIONAL CORP/MA CENTRAL INDEX KEY: 0001034196 IRS NUMBER: 042840139 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13D/A BUSINESS ADDRESS: STREET 1: 75 STATE STREET CITY: BOSTON STATE: MA ZIP: 02109 BUSINESS PHONE: 6179519400 MAIL ADDRESS: STREET 1: 75 STATE STREET CITY: BOSTON STATE: MA ZIP: 02109 SC 13D/A 1 d494224dsc13da.htm SCHEDULE 13D AMENDMENT NO. 5 Schedule 13D Amendment No. 5

SCHEDULE 13D

 

CUSIP No. 00767E102    Page 1 of 11

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

SCHEDULE 13D

(Rule 13d-101)

INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO

RULES 13d-1(a) AND AMENDMENTS THERETO FILED

PURSUANT TO RULE 13d-2(a)

(Amendment No. 5 – Exit Filing)1

 

 

Aegerion Pharmaceuticals, Inc.

(Name of Issuer)

Common Stock, par value $0.001

(Title of Class of Securities)

00767E102

(CUSIP Number)

Jarlyth H. Gibson, Compliance Officer 617-951-9493

C/o Advent International Corporation, 75 State Street, 29th Floor

Boston, MA 02109

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

February 26, 2013

(Date of Event Which Requires Filing of This Statement)

 

 

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(e), 13d-1(f) or 13d-1(g), check the following box:.  ¨

 

 

Note. Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7(b) for other parties to whom copies are to be sent.

 

 

(Continued on following pages)

(Page 1 of 11 pages)

 

1 

The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

 

 

SCHEDULE 13D

 

CUSIP No. 00767E102   Page 2 of 11

 

  1   

Name of reporting person

I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (ENTITIES ONLY)

 

Advent International Corporation

  2  

Check the appropriate box if a member of a group*

(a)  x        (b)  ¨

 

  3  

SEC use only

 

  4  

Source of funds

 

    WC

  5  

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

 

  6  

Citizenship or place of organization

 

    Delaware

Number of

shares

beneficially

owned by

each

reporting

person

with

 

      7    

Sole voting power

 

    1,352,222

     8   

Shared voting power

 

    None

     9   

Sole dispositive power

 

    1,352,222

   10   

Shared dispositive power

 

    None

11  

Aggregate amount beneficially owned by each reporting person

 

    1,352,222

12  

Check box if the aggregate amount in Row (9) excludes certain shares    ¨

 

13  

Percent of class represented by amount in Row (9)

 

    4.71%

14  

Type of reporting person*

 

    CO, IA

 

SCHEDULE 13D

 

CUSIP No. 00767E102   Page 3 of 11

 

  1   

Name of reporting person

I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (ENTITIES ONLY)

 

Advent International LLC

  2  

Check the appropriate box if a member of a group*

(a)  x        (b)  ¨

 

  3  

SEC use only

 

  4  

Source of funds

 

    WC

  5  

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

 

  6  

Citizenship or place of organization

 

    Massachusetts

Number of

shares

beneficially

owned by

each

reporting

person

with

 

      7    

Sole voting power

 

    1,337,306

     8   

Shared voting power

 

    None

     9   

Sole dispositive power

 

    1,337,306

   10   

Shared dispositive power

 

    None

11  

Aggregate amount beneficially owned by each reporting person

 

    1,337,306

12  

Check box if the aggregate amount in Row (9) excludes certain shares    ¨

 

13  

Percent of class represented by amount in Row (9)

 

    4.66%

14  

Type of reporting person*

 

    PN

 

SCHEDULE 13D

 

CUSIP No. 00767E102   Page 4 of 11

 

  1   

Name of reporting person

I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (ENTITIES ONLY)

 

AHLS III GP Limited Partnership

  2  

Check the appropriate box if a member of a group*

(a)  x        (b)  ¨

 

  3  

SEC use only

 

  4  

Source of funds

 

    WC

  5  

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

 

  6  

Citizenship or place of organization

 

    Massachusetts

Number of

shares

beneficially

owned by

each

reporting

person

with

 

      7    

Sole voting power

 

    1,337,306

     8   

Shared voting power

 

    None

     9   

Sole dispositive power

 

    1,337,306

   10   

Shared dispositive power

 

    None

11  

Aggregate amount beneficially owned by each reporting person

 

    1,337,306

12  

Check box if the aggregate amount in Row (9) excludes certain shares    ¨

 

13  

Percent of class represented by amount in Row (9)

 

    4.66%

14  

Type of reporting person*

 

    PN

 

SCHEDULE 13D

 

CUSIP No. 00767E102   Page 5 of 11

 

  1   

Name of reporting person

I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (ENTITIES ONLY)

 

Advent Healthcare and Life Sciences III Limited Partnership

  2  

Check the appropriate box if a member of a group*

(a)  x        (b)  ¨

 

  3  

SEC use only

 

  4  

Source of funds

 

    WC

  5  

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

 

  6  

Citizenship or place of organization

 

    Delaware

Number of

shares

beneficially

owned by

each

reporting

person

with

 

      7    

Sole voting power

 

    541,932

     8   

Shared voting power

 

    None

     9   

Sole dispositive power

 

    541,932

   10   

Shared dispositive power

 

    None

11  

Aggregate amount beneficially owned by each reporting person

 

    541,932

12  

Check box if the aggregate amount in Row (9) excludes certain shares    ¨

 

13  

Percent of class represented by amount in Row (9)

 

    1.89%

14  

Type of reporting person*

 

    PN

 

SCHEDULE 13D

 

CUSIP No. 00767E102   Page 6 of 11

 

  1   

Name of reporting person

I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (ENTITIES ONLY)

 

Advent Healthcare and Life Sciences III A Limited Partnership

  2  

Check the appropriate box if a member of a group*

(a)  x        (b)  ¨

 

  3  

SEC use only

 

  4  

Source of funds

 

    WC

  5  

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

 

  6  

Citizenship or place of organization

 

    Delaware

Number of

shares

beneficially

owned by

each

reporting

person

with

 

      7    

Sole voting power

 

    795,374

     8   

Shared voting power

 

    None

     9   

Sole dispositive power

 

    795,374

   10   

Shared dispositive power

 

    None

11  

Aggregate amount beneficially owned by each reporting person

 

    795,374

12  

Check box if the aggregate amount in Row (9) excludes certain shares    ¨

 

13  

Percent of class represented by amount in Row (9)

 

    2.77%

14  

Type of reporting person*

 

    PN

 

SCHEDULE 13D

 

CUSIP No. 00767E102   Page 7 of 11

 

  1   

Name of reporting person

I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (ENTITIES ONLY)

 

Advent Partners HLS III Limited Partnership

  2  

Check the appropriate box if a member of a group*

(a)  x        (b)  ¨

 

  3  

SEC use only

 

  4  

Source of funds

 

    WC

  5  

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

 

  6  

Citizenship or place of organization

 

    Delaware

Number of

shares

beneficially

owned by

each

reporting

person

with

 

      7    

Sole voting power

 

    14,916

     8   

Shared voting power

 

    None

     9   

Sole dispositive power

 

    14,916

   10   

Shared dispositive power

 

    None

11  

Aggregate amount beneficially owned by each reporting person

 

    14,916

12  

Check box if the aggregate amount in Row (9) excludes certain shares    ¨

 

13  

Percent of class represented by amount in Row (9)

 

    0.05%

14  

Type of reporting person*

 

    PN

 

SCHEDULE 13D

 

CUSIP No. 00767E102    Page 8 of 11

 

Item 1. Security and Issuer

This statement on Amendment No. 5 to Schedule 13D (“Amendment No. 5”) relates to the Reporting Persons’ beneficial ownership interest in the Common Stock, par value $0.001 per share (the “Common Stock”), of Aegerion Pharmaceuticals, Inc., a Delaware Corporation (the “Issuer”). The address of the principal executive office of the Issuer is 101 Main Street, Suite 1850, Cambridge, Massachusetts 02142. This Amendment No. 5 amends the initial statement on Schedule 13D filed with the Securities and Exchange Commission (the “Commission”) on November 10, 2010 as amended by Amendment No. 1 thereto filed with the Commission on February 1, 2012, Amendment No. 2 thereto filed with the Commission on November 5, 2012, Amendment No. 3 thereto filed with the Commission on February 14, 2013, and Amendment No. 4 thereto filed with the Commission on February 19, 2013 (as so amended, the “Schedule D”). This Amendment No. 5 is being filed by the Reporting Persons to amend Item 5. Terms defined in the Schedule 13D are used herein as so defined.

 

Item 5. Interest in Securities of the Issuer.

Item 5 of the Schedule 13D is hereby amended as set forth in the following table which reports the aggregate number and percentage of the Common Stock beneficially owned by each Reporting Person named in Item 2 of the Schedule 13D (based on 28,714,078 shares of Common Stock outstanding as of February 14, 2013). The table has been amended to reflect sales made on behalf of each Reporting Person since the initial statement was filed. The table has been amended to reflect sales made on behalf of each Reporting Person. The aggregate number and percentage of the Common Stock beneficially owned by each Reporting Person is calculated in accordance with Rule 13d-3.

SCHEDULE 13D

 

CUSIP No. 00767E102    Page 9 of 11

 

Reporting Person

    Number of
Shares
Beneficially
Owned		      Percentage
of Common
Stock
Outstanding		     Number
of Shares
Disposed during
Past 60 Days		  

Advent International Corporation (1)(2)(3)

      1,352,222         4.71 %      235,543   

Advent International LLC (1) (2)

      1,337,306         4.66 %      232,945   

AHLS III GP Limited Partnership (1) (2)

      1,337,306         4.66 %      232,945   

Advent Healthcare and Life Sciences III Limited Partnership (2)

      541,932         1.89 %      94,401   

Advent Healthcare and Life Sciences III A Limited Partnership (2)

      795,374         2.77 %      138,544   

Advent Partners HLS III Limited Partnership(3)

      14,916         0.05 %      2,598   

Total Group

      1,352,222         4.71 %      235,543   

 

(1) Advent International Corporation (“AIC”) is the Manager of Advent International LLC (“AI LLC”) which in turn is the General Partner AHLS III GP (“AHLS III GP”) Limited Partnership which in turn is the General Partner of the indicated Reporting Persons. As such, AIC has the sole power to vote and dispose of the securities owned by the indicated Reporting Persons. The beneficial ownership of AIC, AI LLC and AHLS III GP derive from such power.
(2) Advent International Corporation (“AIC”) is the Manager of Advent International LLC (“AI LLC”) which in turn is the General Partner of AHLS III GP Limited Partnership (“AHLS III GP”) which in turn is the General Partner of the indicated Reporting Persons. As such, AIC has the sole power to vote and dispose of the securities of Advent Healthcare and Life Sciences III Limited Partnership and Advent Healthcare and Life Sciences III A Limited Partnership. The beneficial ownership of AIC, AI LLC and AHLS III GP derive from such power.
(3) Advent International Corporation (“AIC”) is the General Partner the indicated Reporting Persons. As such, AIC has the sole power to vote and dispose of the securities of Advent Partners HLS III Limited Partnership. The beneficial ownership of AIC derives from such power.

SCHEDULE 13D

 

CUSIP No. 00767E102    Page 10 of 11

 

(b) Each of the Reporting Persons listed in the table set forth above has sole voting and dispositive power over the Common Stock beneficially owned by it as indicated above.

(The Remainder of this Page Left Intentionally Blank)

SCHEDULE 13D

 

CUSIP No. 00767E102    Page 11 of 11

 

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

February 28, 2013

 

Advent Healthcare and Life Sciences III Limited Partnership
Advent Healthcare and Life Sciences III A Limited Partnership
By:   AHLS III GP Limited Partnership,
  General Partner
By:   Advent International LLC, General Partner
By:   Advent International Corporation,
  Manager
By:   Jarlyth H. Gibson, Compliance Officer*
Advent Partners HLS III Limited Partnership
By:   Advent International Corporation,
  General Partner
By:   Jarlyth H. Gibson, Compliance Officer*
AHLS III GP Limited Partnership
By:   Advent International LLC, General Partner
By:   Advent International Corporation, Manager
By:   Jarlyth H. Gibson, Compliance Officer*
Advent International LLC
By:   Advent International Corporation, Manager
By:   Jarlyth H. Gibson, Compliance Officer*
Advent International Corporation
By:   Jarlyth H. Gibson, Compliance Officer*
*For all of the above:

/s/ Jarlyth H. Gibson

Jarlyth H. Gibson, Compliance Officer